Scinopharm Taiwan, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 10, 2021
Share
ScinoPharm Taiwan, Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was TWD 641.136 million compared to TWD 542.523 million a year ago. Operating income was TWD 110.353 million compared to TWD 44.658 million a year ago. Net income was TWD 90.238 million compared to TWD 35.356 million a year ago. Basic earnings per share was TWD 0.11 compared to TWD 0.04 a year ago.
ScinoPharm Taiwan Ltd is a Taiwan-based company mainly engaged in the research, development, manufacture and sale of active pharmaceutical ingredients. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The Company is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The Company operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
SCINOPHARM TAIWAN, LTD. 
